Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. The company’s development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead vaccine candidate is a universal pneumococcal vaccine based on the platform BERA. The company also develops projects in immuno-oncology, Chlamydia, ETEC, Covid-19, and Tuberculosis. The company was incorporated in 2012 and is based in Uppsala, Sweden.
तुलना करने के लिए मीट्रिक्स | ABERA | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधABERAपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −13.4x | −3.0x | −0.4x | |
PEG अनुपात | 0.02 | −0.09 | 0.00 | |
क़ीमत/बुक | 7.2x | 2.6x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 11.8x | 16.7x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 137.7% | 46.2% | |
उचित मूल्य अपसाइड | अनलॉक करें | −18.2% | 7.2% | अनलॉक करें |